Patients receiving Pola-R-CHP were found to be more likely to be male (58% vs 54%), younger (mean age, 75.0 vs 77.5 years), ...

A recently cleared phase 3 study (NCT06051409) will evaluate olverembatinib combined with chemotherapy as a first-line ...

Based on the primary PFS analysis of EMBER-3, the FDA approved single-agent imlunestrant in September 2025 for the treatment of patients with ER+/HER2– ESR1 m advanced breast cancer with disease ...

Infection management in hematologic malignancies is critical due to higher mortality risks, necessitating improved communication between patients and providers. Remote therapeutic monitoring platforms ...

The FDA approved niraparib and abiraterone acetate plus prednisone for BRCA2-mutated mCSPC, based on the AMPLITUDE trial's rPFS results. FDA approves a new treatment combining niraparib and ...

Long-term follow-up in the PALLAS study showed no overall survival benefit with palbociclib plus endocrine therapy compared to endocrine therapy alone in hormone receptor-positive, HER2-negative ...

Hormone replacement therapy (HRT) does not increase breast cancer risk in BRCA1/BRCA2 carriers, with estrogen-alone formulations showing a lower risk. The study used a matched-pair design to control ...

Early results from the OLYMPIA-3 trial reveal odronextamab plus CHOP chemotherapy shows promising efficacy for untreated ...

Explore the advantages and challenges of long-term red blood cell transfusions for low-risk MDS patients, focusing on quality ...

The Olympia-3 study explores odronextamab as a promising chemo-free treatment for untreated diffuse B-cell lymphoma patients.

Long-term follow-up of the IMEG trial reveals potential survival benefits of a metal stent in low-risk MDS patients, ...

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks ...